CURESPONSE Showcases Breakthrough Functional Oncology Platform at Tumour Models London Summit 2024
London, December 2024 – CURESPONSE participated in the Tumour Models London Summit 2024, where Dr. Vered Bar, Vice President of R&D, delivered a featured session during the company’s hosted lunch titled:“Future-Proofing Pipeline Compounds with Breakthrough Functional Technology.” During the session, Dr. Bar presented CURESPONSE’s pioneering ex-vivo functional platform, designed to transform oncology drug development by […]
CURESPONSE Awarded European Patent for Functional Discovery of Novel Combination Therapy in Colorectal Cancer
Tel Aviv, Israel – April 2025 — CURESPONSE Ltd. is pleased to announce that the European Patent Office (EPO) has granted a new patent recognizing the company’s pioneering use of its proprietary cRESPONSE™ ex vivo organ culture (EVOC) platform to discover and validate novel, patient-specific therapeutic strategies in cancer. The patent protects the use of […]
CURESPONSE Joins Israel’s Health-Tech Roadshow to the U.S., Showcasing Innovation in Functional Precision Oncology
U.S., February 2025 – CURESPONSE was honored to participate in the Israel Health-Tech Roadshow to the U.S., a strategic initiative led by Startup Nation Central to spotlight the country’s most promising healthcare innovators. Selected from hundreds of companies, CURESPONSE was one of 16 pioneering startups chosen to represent Israeli health-tech excellence across major U.S. healthcare […]
CURESPONSE to collaborate with EDX Medical Group plc, on marketing the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.
EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse Ltd, to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark. EDX Medical will initiate commercial activities to […]
Curesponse selected for ‘Israeli Innovation Dream Team’ 2024/2025
Curesponse has been selected by a special committee from hundreds of nominee companies to be featured as part of the esteemed ‘Israeli Innovation Dream Team’ for 2024/2025.This recognition positions Curesponse as a leading Israeli breakthrough, representing innovative advancements to visiting delegations at the Israeli Innovation Center—the first and largest visitor’s center of its kind.The Israeli […]
A New Publication Highlights the Use of cResponse in the Assessment of Response to Treatments for Pancreatic Cancer
A recent study led by Dr. Talia Golan from the Sheba Medical Center and Dr. Chani Stossel at the Oncology Institute titled; Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting, studied 125 patients with this kind of cancer, grouping them by how they responded to certain […]
Curesponse discusses with the Jerusalem Post its innovative cResponse™ test that helps tailor the optimal treatment for breast cancer patients.
Breast cancer treatment has improved a lot in the last decade with more understanding and treatment options available, leading to a high cure rate in early stages. There are many types of treatments like chemotherapy, hormonal therapy, targeted therapies, etc. The challenge is to pick the best treatment for a patient, considering effectiveness and side […]
Curesponse discuss with the Jerusalem Post its cResponse test that can predict which drugs will benefit individual cancer patients.
The Weizmann Institute in Israel has developed a technology that can test a cancer patient’s tumor to find out which drugs will work best for them. This technology, created by Curesponse, uses a test called cResponse™. It grows a piece of the patient’s tumor in the lab and then exposes it to different drugs to […]
Curesponse Presents Positive Preliminary Clinical Results from a Multi-Center UK Study at AACR
Curesponse, a pioneering oncology company, recently announced preliminary clinical results from a multi-center UK study at the American Association for Cancer Research meeting in Florida. Curesponse’s clinical results from the first 15 patients showcased the predictive strength of cResponse, an AI-based genomic-functional drug prioritization technology. The UK study, combined with Curesponse’s clinical results from a […]
Curesponse discusses its cancer prediction cResponse™ test with Ynet (in hebrew)
Israeli technology developed at the Weizmann Institute has led to the creation of a groundbreaking cancer prediction test that can predict with 90% accuracy which drugs will benefit cancer patients. This can significantly increase the chances of treatment success and save patients from ineffective treatments and unnecessary side effects. The breakthrough cancer prediction technology, developed […]